Nanoscope Therapeutics Inc. today announced that Aaron Osborne , Chief Medical Officer, will give a presentation on clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform.
| Nanoscope’s Chief Medical Officer, Dr. Aaron Osborne, to give a presentation on Nanoscope’s Optogenetic Approach for Vision Restoration DALLAS, Aug. 26, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Aaron Osborne, Chief Medical Officer, will give a presentation on clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform and participate in a panel titled “Gene Therapy Platforms for Macular Disease - Are They Worth the Money?” at the Retina Forum, taking place August 31, 2022, in Hamburg, Germany and online as part of the Ophthalmology Futures Forums.
Details for the presentation are as follows: Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration In addition to highlighting the benefits of MCO gene therapy, Dr. Osborne will detail Nanoscope’s Phase 2b RESTORE trial from its lead clinical program. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in H1 2023. About Nanoscope Therapeutics Inc. Investor Contact:
SOURCE Nanoscope Therapeutics |
View original content to download multimedia:
